University of Kentucky Markey Cancer Center - Cancer Center Support Grant

描述（由申请人提供）：马基癌症中心（MCC）是一家专门的矩阵癌症中心，作为肯塔基州大学（英国）和英国医疗保健企业的组成部分，近年来在MCC主任B博士的领导下经历了急剧的扩张。马克·埃弗斯在该中心发展的这一点上，MCC通过国家癌症研究所（NCI）癌症中心支持赠款寻求支持，以利用这一势头，并通过癌症研究，预防和患者护理的综合计划，推动肯塔基州，特别是阿巴拉契亚肯塔基州癌症死亡率的可衡量的降低。在一个在众多癌症指标上领先全国的州，包括全国最高的癌症死亡率，对NCI癌症中心指定的需求尤为迫切。MCC坐落在一个校园内，所有六个健康专业学院彼此相邻，提供了丰富的跨学科的历史， 合作，癌症预防和控制的杰出计划，产生了开创性的工作，在阿巴拉契亚肯塔基州，在癌症生物学和DNA修复和氧化应激全国知名的基础研究计划，并通过药学院的前五名补充转化治疗方案。 这些优势在MCC的四个主题研究项目中得到了融合：癌细胞生物学和信号传导;癌症预防和控制;药物发现，交付和转化治疗;氧化还原损伤和修复。目前，MCC的108名研究和副研究成员在整个大学的7个学院的24个部门任职（在过去3年中招募了25名新教师）。MCC成员为144个研究项目提供赠款，年度综合（直接+间接）金额超过3050万美元，其中超过1130万美元（37%）来自NCI。三年来，治疗性临床试验增加了130%以上，MCC的可分配空间增加了40%，包括最先进的研究空间翻了一番。此外，六个共享资源通过为专业知识和先进方法提供强大的基础设施来促进尖端研究。它们包括：生物标本和组织采购;生物统计学;癌症研究信息学;临床研究和数据管理;流式细胞术和细胞分选;以及癌症自由基生物学。管理协委会目前已做好充分准备迎接新的挑战，并继续朝着最大限度地利用这些优势的关键战略方向发展。

DESCRIPTION (provided by applicant): The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics; and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement; Biostatistics; Cancer Research Informatics; Clinical Research and Data Management; Flow Cytometry and Cell Sorting; and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.